Industry excitement surrounding the development of digital health platforms and applications is growing, as patients look for new ways to access healthcare during the COVID-19 pandemic. In April, the FDA relaxed its requirements for public use of some digital therapeutics during the pandemic, which led to new products rushing into the market almost overnight. However, large insurers have taken a more hesitant approach to coverage of new digital therapeutics, even in cases where products have received FDA clearance based on a traditional clinical trial process and evidence development.
This is particularly true in the case of digital therapeutics, defined here as FDA-cleared prescription digital applications used by patients...
